title: Ginseng panaxoside Rb1 reduces body weight in diet-induced obese mice.
abstract: Crude extracts from ginseng demonstrated anti-obesity properties. Ginsenoside Rb1 is the main component of ginseng, however, there are only few studies examining its effects in obesity. In the present study, we evaluated its potential anti-obesity effects in the murine model of diet-induced obesity. Seventy male C57BL/6 mice were randomly divided to consume for 12 weeks either chow diet (N = 8) or high-fat (HF) diet (N = 62). The latter mice were then divided into four groups: diet-induced obesity group (DIO; N = 10), obesity-resistant group (OR; N = 10), HF group (N = 5), and the group whose diet was changed from HF to normal diet (DC; N = 5). Intraperitoneal injections of Rb-1 were administered daily to mice in the DIO and OR groups for 3 weeks. Body weight and energy intake were monitored, and fasting blood glucose, lipids, neuropeptide Y, Y2 receptor, and peptide YY were quantified. Compared with HF group, weight gain and food intake of DIO mice with Rb-1 injection was significantly decreased (p < 0.05). Further, levels of blood glucose and some lipids were also decreased in DIO-Rb1 group compared with HF group. Furthermore, Rb1 was also found to modulate serum levels of PYY and NPY, and mRNA expression of NPY, Y2 receptor and PYY in tissue samples of DIO mice. Taken together, ginsenoside Rb1 may be useful in the treatment of obesity via modifying the serum content and mRNA expression of NPY, Y2 receptor and PYY.
authors.affiliation: Department of General Surgery, Chengdu Military General Hospital, 270 Rongdu Road, Chengdu, 610083, China, helenmedic@gmail.com.
authors.forename: Ning
authors.initials: N
authors.lastname: Lin
authors.forename: Dong-Lian
authors.initials: DL
authors.lastname: Cai
authors.forename: Di
authors.initials: D
authors.lastname: Jin
authors.forename: Yi
authors.initials: Y
authors.lastname: Chen
authors.forename: Jiao-Jiao
authors.initials: JJ
authors.lastname: Shi
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects*; D004032:Diet; D059305:Diet, High-Fat; D004334:Drug Administration Schedule; D036145:Ginsenosides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009478:Neuropeptide Y / Q000097:blood / Q000235:genetics / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005894:Panax / Q000737:chemistry* / Q000378:metabolism; D019894:Peptide YY / Q000097:blood / Q000235:genetics / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000032:analysis / Q000235:genetics / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D036145:Ginsenosides; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor; D019894:Peptide YY; C442759:ginsenoside Rb1